PATIENT REPORTED OUTCOMES IN THE DIAGNOSIS AND TREATMENT OF LYMPHOMA
Dr Elizabeth Goodall,
Haematologist and PhD student
Austin Health, Olivia Newton-John Cancer Research Institute & Monash Health, Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne | February 2025
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
After completing her undergraduate degree in Medical Sciences at La Trobe University she went onto complete an Honours degree in malaria research before enrolling in Medicine at Monash University, Gippsland, Victoria in Australia.
Following medical school, she trained at Austin Health and successfully completed both clinical and laboratory haematology programs before moving to a lymphoma clinical trials fellowship at Monash Health. This fellowship provided essential clinical skills and has fostered a life-long interest in improving patient access to trials, finding ways to better select therapies for patients with blood cancers and learning more about the patient’s experience throughout treatment.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
This has led to her PhD on Patient Reported Outcomes (PROs) which will focus on the accurate documentation of the patient experience and learn how best to include this data for future clinical trial design, an essential component of obtaining excellent treatment outcomes. For this work she is the 2025 recipient of the Haematology Society of Australia and New Zealand and the Leukaemia Foundation New Investigator PhD Scholarship which will provide invaluable support throughout the PhD.
-
Respiratory health and the microbiome in the lung environment
Dr Taylor leads the Respiratory Health Group within the Microbiome and Host Health Program. His research employs tailored techniques that allow the lung environment to be characterised to a high level of accuracy, including detailed measurements of airway microbiology (microbiome), mucus composition, and inflammation. This information is used to identify predictive markers of chronic lung disease severity as well as determine effective forms of therapy.
-
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
-
Supportive care for people living with or beyond cancer treatment
Dr Hannah Wardill is a Hospital Research Foundation Fellow and lead of the Supportive Oncology Research Group (SORG), in the School of Biomedicine, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI). She is an Executive Board Member of the Multinational Association for Supportive Care in Cancer / International Society for Oral Oncology (MASCC/ISOO) and Chair of both MASCC/ISOO Patient Partnership Committee & the Palliative Care Clinical Studies Collaborative (PaCCSC) Cancer Symptom Trials (Gut Dysfunction Node; supported by Cancer Australia).
